Skip to content

Improving Sexual Function After Myocardial Infarction

Improving Sexual Function After Myocardial Infarction - a Randomized Controlled Trial.

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05312320
Acronym
Sex/MI
Enrollment
1200
Registered
2022-04-05
Start date
2022-11-07
Completion date
2024-11-30
Last updated
2022-11-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction, Sexual Function Disturbances

Brief summary

The study is completely digital. Men and women who recently had an MI will be invited through a written brochure that will be present in all Norwegian departments of cardiology. Post-MI patients can check the investigators web site (www.sefh.no) to determine whether they are eligible for the study. After consent and answering the baseline questionnaire, each participant will be randomized to either the intervention or control group. Control group: Standard surveillance after MI (no specific focus on sexual activity and functioning) Intervention group: Online sexual counselling including a short information film. In order to assess the generalizability of the results, we will compare the age, sex and MI treatment of the respondents with data on Norwegian MI-patients in general.

Detailed description

The investigators will include 600 women and 600 men within 4 weeks after an acute MI. The investigators will invite the same number of women and men from the general population, invited through mass and social media. All participants will be provided the same questionnaire at 4 weeks. Then outcome data will be obtained by a follow-up quest after 6 and 12 months. The intervention is a film with the following main message: * Sexual activity after MI does not increase risk of recurrence or death * Sexual activity is associated with improved outcome after MI * Resuming sexual activity as normal is recommended and completely safe

Interventions

OTHERInformation film

* Sexual activity after MI does not increase risk of recurrence or death * Sexual activity is associated with improved outcome after MI * Resuming sexual activity as normal is recommended and completely safe

Sponsors

Oslo University Hospital
CollaboratorOTHER
Sorlandet Hospital HF
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 110 Years
Healthy volunteers
No

Inclusion criteria

* Men and women ≥18 years old * Acute MI during the last 6 weeks * Informed consent for participation

Exclusion criteria

* Lack of ability to cooperate * Known alcohol- or drug-abuse, or use of narcotics * Pregnancy or breast-feeding * Serious comorbidity with a life expectancy \<12 months * Unstable or refractory angina * Uncontrolled hypertension * Congestive heart failure (NYHA class III/IV) * High-risk arrhythmias * Hypertrophic obstructive and other cardiomyopathies * Severe valvular disease

Design outcomes

Primary

MeasureTime frameDescription
Does specific sexual counselling improve sexual functioning in post-MI?12 monthsThe investigators will measure sexual function by Brief Sexual Function Inventory (BSFI) for male participants and Female Sexual Function Index (FSFI) for female participants at 6 and 12 months after their MI.
Changes in sexual activity and functioning after MI12 monthsThe investigators will measure sexual activity and function at baseline, and 6 and 12 months after MI. The investigators will measure sexual function by Brief Sexual Function Inventory (BSFI) for male participants and Female Sexual Function Index (FSFI) for female participants.
Establish predictors of improved sexual functioning in post-MI patients12 monthsIn order to identify MI patients at risk of sexual dysfunction, the participants will answer questionnaires on quality of life (RAND-12), depression and anxiety (HADS), demographic data, comorbidity, medications and other factors that may have impact on sexual function.

Countries

Norway

Contacts

Primary ContactVibeke Salvesen, MD
vibeke.salvesen@sshf.no+47 47304802
Backup ContactNora Johansen, Ph.D
nora.johansen@sshf.no+47 40496612

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026